"Qichensheng" completed several hundred million yuan of pre-A + round financing
Qichensheng has recently completed several hundred million yuan of pre-A + round financing. The current round of financing is led by the CICC Qide innovative biomedical equity investment fund of CICC capital, and the original shareholder sunshine capital continues to invest. The funds raised will be used to support the phase I clinical study of qichensheng's self-developed mRNA vaccine to be launched within this year. Founded at the end of 2015 and headquartered in Yizhuang, Beijing, Qichen is a biopharmaceutical company focusing on the technological innovation and R & D of mRNA, nucleic acid, cellular drugs and related industrial chain.
This text is a result of machine translation.
Related companies：
Briefing Jun 20, 2022 04:54 PM
· Technology
The official results of the French parliamentary elections were announced, and the ruling party coalition held a relatively large number of seats
In-depth
Briefing May 21, 2022 06:44 AM
· Financials
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Apr 26, 2022 12:26 PM
Apr 21, 2022 07:07 PM
Apr 18, 2022 06:30 PM
Jun 29, 2021 11:48 PM
Briefing Oct 23, 2021 09:18 AM
· Technology
The software evaluation center of China automobile center has reached chip certification cooperation with Ziguang Guowei
Healthcare
Guideline Issued by China's 17 Departments Decides to Put ART into Health Insurance
China's 17 government departments released a guideline to boost population growth on August 16. The guideline states that the Chinese government will include Assisted Reproductive Technology in health insurance.
Aug 17, 2022 04:03 PM
Briefing Sep 13, 2021 10:05 AM
Semiconductor chip stocks fell in early trading
See more
Read next
Insight
In-depth
Automotive
Envisioning Future Mobility in China: the Status and Prospect of DMS
Aug 18, 2022 11:19 AM
Insight
In-depth